Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015

Aratana Therapeutics, Inc. PETX, a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today provided commentary on clinical study data involving ADXS31-164 (AT-014) that was recently presented during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2015. ADXS31-164 is a novel Lm-LLO immunotherapy developed by Advaxis, Inc. ADXS to target HER2 receptor expressing cancers.  In March 2014, Aratana licensed ADXS31-164 from Advaxis for the treatment of canine osteosarcoma and other cancers, adding the drug product to its pipeline of cancer therapeutics as AT-014. On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania's School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma (Poster Board #7; Abstract #LB-113).  The data suggests that ADXS31-164 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!